Medicare Enrolled
Eric Fox
Hematology & Oncology · Bryn Mawr, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Fox from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Fox?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Fox
Eric Fox is a hematology & oncology specialist in Bryn Mawr, PA, with 10 years of NPI registration. Based on federal Medicare data, Fox performed 27,581 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Fox received a total of $11,591 from 60 pharmaceutical and/or device companies across 428 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Fox is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 10 years of NPI registration
▲ Top 16% volume in PA
$11,591 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗27,581
Medicare services
Top 16% in PA for hematology & oncology
Not available
Unique patients (not deduplicated)
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
22,500 | $1 | $3 |
| Denosumab injection (Prolia/Xgeva) | 2,460 | $17 | $65 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
634 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 390 | $1 | $118 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
304 | $67 | $141 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
270 | $8 | $35 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
159 | $8 | $17 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
149 | $13 | $91 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
129 | $101 | $194 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
87 | $11 | $78 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
68 | $109 | $649 |
| New patient office visit, complex (60-74 min) | 62 | $170 | $339 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
54 | $53 | $220 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
49 | $40 | $115 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
40 | $139 | $399 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
39 | $125 | $296 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
36 | $60 | $205 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
33 | $24 | $140 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
26 | $1 | $11 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
25 | $1 | $8 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
24 | $54 | $305 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
22 | $24 | $138 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
21 | $144 | $273 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
82.2% high complexity
13.8% medium
4.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$11,591
Total received (2018-2024)
Avg $1,656/year across 7 years
Top 21% in PA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
60
Companies
428
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,596
2023
$3,946
2022
$547
2021
$123
2020
$411
2019
$822
2018
$146
Payments by company (2024)
AstraZeneca Pharmaceuticals LP
$1,138
PFIZER INC.
$380
ABBVIE INC.
$312
Novartis Pharmaceuticals Corporation
$275
Merck Sharp & Dohme LLC
$256
Daiichi Sankyo Inc.
$231
Astellas Pharma US Inc
$220
Lilly USA, LLC
$207
Incyte Corporation
$200
E.R. Squibb & Sons, L.L.C.
$199
Ipsen Biopharmaceuticals, Inc
$190
Genmab U.S., Inc.
$183
Eisai Inc.
$149
Celgene Corporation
$118
Bayer Healthcare Pharmaceuticals Inc.
$117
Karyopharm Therapeutics Inc.
$117
Gilead Sciences, Inc.
$109
Janssen Biotech, Inc.
$105
Takeda Pharmaceuticals U.S.A., Inc.
$97
Genentech USA, Inc.
$97
Mirati Therapeutics, Inc.
$89
PharmaEssentia USA Corporation
$70
SHIELD THERAPEUTICS INC
$62
Janssen Pharmaceuticals, Inc
$61
Alnylam Pharmaceuticals Inc.
$61
ARRAY BIOPHARMA INC
$61
Alexion Pharmaceuticals, Inc.
$57
Amneal Pharmaceuticals LLC
$56
JAZZ PHARMACEUTICALS INC.
$50
SERVIER PHARMACEUTICALS LLC
$46
SOBI, INC
$43
Exelixis Inc.
$43
Adaptive Biotechnologies Corporation
$30
Blueprint Medicines Corporation
$27
GENZYME CORPORATION
$24
Apellis Pharmaceuticals, Inc.
$21
MorphoSys, US Inc.
$21
Stemline Therapeutics Inc.
$18
TerSera Therapeutics LLC
$18
Ferring Pharmaceuticals Inc.
$18
GlaxoSmithKline, LLC.
$17
Top 3 companies account for 32.7% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$2,178
AstraZeneca Pharmaceuticals LP
$1,789
PFIZER INC.
$622
Daiichi Sankyo Inc.
$615
Lilly USA, LLC
$474
E.R. Squibb & Sons, L.L.C.
$444
Incyte Corporation
$400
Astellas Pharma US Inc
$375
ABBVIE INC.
$358
Merck Sharp & Dohme LLC
$332
Novartis Pharmaceuticals Corporation
$275
Celgene Corporation
$261
Eisai Inc.
$236
Ipsen Biopharmaceuticals, Inc
$219
Genmab U.S., Inc.
$208
Takeda Pharmaceuticals U.S.A., Inc.
$178
Seagen Inc.
$150
Genentech USA, Inc.
$144
Mirati Therapeutics, Inc.
$144
Karyopharm Therapeutics Inc.
$140
GENZYME CORPORATION
$125
Gilead Sciences, Inc.
$124
Pharmacyclics LLC, An AbbVie Company
$120
Seattle Genetics, Inc.
$118
Bayer Healthcare Pharmaceuticals Inc.
$117
Stemline Therapeutics Inc.
$109
MorphoSys, US Inc.
$93
Alnylam Pharmaceuticals Inc.
$76
PharmaEssentia USA Corporation
$70
SOBI, INC
$69
SHIELD THERAPEUTICS INC
$62
GlaxoSmithKline, LLC.
$61
Janssen Pharmaceuticals, Inc
$61
ARRAY BIOPHARMA INC
$61
SERVIER PHARMACEUTICALS LLC
$60
Amgen Inc.
$58
Alexion Pharmaceuticals, Inc.
$57
Amneal Pharmaceuticals LLC
$56
JAZZ PHARMACEUTICALS INC.
$50
Exelixis Inc.
$43
Apellis Pharmaceuticals, Inc.
$41
Taiho Oncology, Inc.
$39
Adaptive Biotechnologies Corporation
$30
Regeneron Healthcare Solutions, Inc.
$30
Blueprint Medicines Corporation
$27
Foundation Medicine, Inc.
$25
G1 Therapeutics, Inc.
$23
Global Blood Therapeutics, Inc.
$23
Telix Pharmaceuticals
$22
AVEO Pharmaceuticals, Inc.
$22
Boehringer Ingelheim Pharmaceuticals, Inc.
$22
Merck Sharp & Dohme Corporation
$20
RECORDATI_RARE_DISEASES_INC.
$20
Kite Pharma, Inc.
$18
TerSera Therapeutics LLC
$18
Ferring Pharmaceuticals Inc.
$18
Coherus Biosciences Inc.
$17
AMAG Pharmaceuticals, Inc.
$16
Bayer HealthCare Pharmaceuticals Inc.
$15
Sumitomo Pharma America, Inc.
$13
Top 3 companies account for 39.6% of all-time payments
Associated products mentioned in payments ›
ACCRUFER · ADCETRIS · ADSTILADRIN · ALIMTA · ALUNBRIG · AVASTIN · AYVAKIT · Abraxane · BESREMI · BLENREP · BRAFTOVI · BRILINTA · Blincyto · CABOMETYX · CALQUENCE · CARVYKTI · CHANTIX · COSELA · CYRAMZA · Columvi · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · ENHERTU · EPKINLY · ERLEADA · Empaveli · Enhertu · Epkinly · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · GIVLAARI · IBRANCE · ILLUCCIX · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Inrebic · JAKAFI · JARDIANCE · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MONJUVI · NINLARO · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Orserdu · PADCEV · PANHEMATIN · PEMAZYRE · PLUVICTO · Padcev · Phesgo · Pomalyst · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · Stivarga · TAGRISSO · TECVAYLI · TUKYSA · Tecentriq · Tibsovo · Tivdak · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VONJO · Venclexta · Voranigo · Vyloy · WAINUA · XALKORI · XARELTO · XPOVIO · Xermelo · Xospata · Xtandi · Yescarta · ZEPZELCA · clonoSEQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
289
County median income
$88,576
Nearest hospital to ZIP centroid (approximate)
BRYN MAWR HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Fox is a mixed practice specialist, with above-average Medicare volume (top 16% in PA).
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Fox experienced with iron infusion (injectafer)?
Based on Medicare claims data, Fox performed 22,500 iron infusion (injectafer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Fox receive payments from pharmaceutical companies?
Yes. Fox received a total of $11,591 from 60 companies across 428 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Fox's costs compare to other hematology & oncology specialists in Bryn Mawr?
Fox's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Fox) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Bryn Mawr
Browse hematology & oncology specialists in Bryn Mawr ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in PA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in PA
Which PA hematology & oncology specialists receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology